Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Faculty Publications Book Chapter Faculty Publications- Book Chapter Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Creator An entity primarily responsible for making the resource Beerannavar, Chaitra Rangappa; Koshi, Sandra Mariya Title A name given to the resource Regulatory and strategic challenges of patent evergreening in the MedTech industry: An analysis of competition law implications Date A point or period of time associated with an event in the lifecycle of the resource 01-01-2025 Source A related resource from which the described resource is derived Strategic Management, Regulatory Challenges, and Global Governance of MedTech;pp.149-183 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.4018/979-8-3373-1205-7.ch007" target="_blank" rel="noreferrer noopener">https://doi.org/10.4018/979-8-3373-1205-7.ch007</a> <br /><br /><a href="https://www.scopus.com/pages/publications/105007734553?origin=resultslist" target="_blank" rel="noreferrer noopener">https://www.scopus.com/pages/publications/105007734553?origin=resultslist</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Beerannavar C.R., Christ University, India; Koshi S.M., Christ University, India Description An account of the resource Patent evergreening is a strategy used by pharmaceutical companies to extend their market exclusivity through minor modifications of existing drugs, often without significant therapeutic advancements. This practice raises concerns about access to affordable medicines, particularly in developing countries like India, where high drug prices impact public health. A comparative analysis with the European Union (EU) reveals that while India relies on patent law restrictions, the EU employs competition law under Article 102 of the Treaty on the Functioning of the European Union (TFEU) to regulate evergreening. Cases such as AstraZeneca v. European Commission demonstrate the EU's effects-based approach to curbing anti-competitive patent strategies. This study highlights the gaps in India's regulatory framework, emphasizing the need for greater coordination between the Indian Patent Office (IPO) and the Competition Commission of India (CCI), and adopting an effects-based approach are crucial to preventing evergreening while ensuring both innovation and consumer welfare. 2025, IGI Global Scientific Publishing. All rights reserved. Publisher An entity responsible for making the resource available IGI Global Relation A related resource ISBN: 979-833731207-1; 979-833731205-7; Language A language of the resource English Type The nature or genre of the resource Book chapter Rights Information about rights held in and over the resource Restricted Access; Hardcopy may be available in the library Format The file format, physical medium, or dimensions of the resource online